Handheld Fan Direction for Breathlessness in Chronic Heart and Lung Disease

November 6, 2026 updated by: Mohamed Fakhry Ahmed Salem, Alexandria University

Fan-to-Face Versus Fan-to-Leg Versus No Fan on Exertional Breathlessness and Exercise Capacity With Stable Chronic Cardiopulmonary Disease: A Mixed Method Three-Arm Randomized Controlled Trial

People with chronic heart failure or chronic lung disease (such as COPD or interstitial lung disease) often feel short of breath when they exert themselves. A handheld fan blowing air on the face may ease this feeling, but it is not clear whether the benefit lasts with longer home use, whether it depends on the direction of the airflow, or whether it works in patients with heart disease and in hot climates.

This study will compare three conditions in adults with stable chronic heart and/or lung disease who become breathless on exertion: (1) a handheld fan directed at the face, (2) a handheld fan directed at the leg, and (3) no fan (usual care). Participants will be randomly assigned (1:1:1) to one of the three groups. The two fan groups will use the fan at home for 12 weeks. The no-fan group will receive a fan after the final assessment. The person measuring outcomes will not know which group each participant is in.

The main outcome is breathlessness (Borg 0-10 scale) in the 5 minutes after a 6-minute walk test at week 12. Other outcomes include walking distance, recovery time, breathlessness severity and impact (Dyspnoea-12), functional class, global change in breathlessness, fan use and acceptability, and emergency visits or hospital admissions.

The study also includes interviews with about 24 to 30 participants from the three groups after week 12, to understand how the fan was used, how acceptable it was, and how heat and humidity affected it. Trial and interview findings will be analysed separately and then combined.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

129

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Alexandria, Egypt, 21511
        • Faculty of Nursing, Alexandria University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults with chronic heart failure and/or chronic lung disease (for example chronic obstructive pulmonary disease or interstitial lung disease) confirmed by a cardiologist or chest physician
  • Stable condition: heart failure NYHA class II to III, and no exacerbation of lung disease in recent weeks, confirmed with the treating specialist
  • Breathlessness on exertion, with an MRC dyspnoea grade and a Borg score after the 6-minute walk test at or above a minimum set in advance [FILL: e.g. Borg >= 3]
  • Stable medication, with no marked change in recent weeks [FILL: period set by the treating specialist]
  • Able to walk, answer the questionnaires and give written informed consent

Exclusion Criteria:

  • Acute heart failure, an acute exacerbation of lung disease, or a recent hospital admission
  • Another dominant cause of breathlessness (for example severe anemia, pulmonary embolism or neuromuscular disease)
  • Severe lung disease needing oxygen at rest
  • Unstable angina, recent myocardial infarction, or any condition that prevents walking or raises risk
  • Cognitive impairment that prevents responding, or inability to use the fan
  • Participation in another trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fan-to-Face

Handheld battery-operated fan directed at the face whenever the participant feels breathless, for 12 weeks at home. Participants receive training and a teach-back check at week 0 and keep a daily diary. Usual care continues unchanged.

Battery-operated handheld fan (same model and speed in both fan arms) directed at the face at a distance of about 15 to 30 cm whenever the participant feels breathless, for a set time per use after training. Used at home for 12 weeks.

Experimental: Fan-to-Leg

Same handheld fan (same model and speed) directed at the leg at the same distance and for the same duration whenever the participant feels breathless, for 12 weeks at home. Training, teach-back, diary and usual care are the same as in the fan-to-face arm.

The same handheld fan directed at the leg at the same distance and for the same duration per use. Used at home for 12 weeks as an active comparator.

No Intervention: No Fan

Usual care for the heart or lung disease for 12 weeks, with a daily diary of breathless episodes and the same visit and phone-call schedule. After the 6-minute walk test, participants rest seated for 5 minutes without a fan. A fan is offered after the week 12 assessment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Breathlessness intensity (Borg CR10) after the 6-minute walk test
Time Frame: Week 12

Breathlessness rated on the Borg CR10 scale (0 = nothing at all, 10 = maximal; higher is worse) during the 5 minutes of seated recovery after a 6-minute walk test, with a fan (fan-to-face and fan-to-leg arms) or seated rest without a fan (no-fan arm). Rated at minutes 1, 3 and 5; the minute used for the primary analysis is [FIX BEFORE SUBMITTING]. The walk test is done without a fan in all arms.

Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
6-minute walk distance
Time Frame: Week 0 and week 12

Distance walked in 6 minutes.

Week 0 and week 12
Recovery time after exertion
Time Frame: Week 0 and week 12

Minutes from the end of the walk test until Borg breathlessness first returns to the pre-test value, asked every minute for 5 minutes (censored at 5 minutes).

Week 0 and week 12
Borg CR10 breathing discomfort
Time Frame: Week 0 and week 12

Borg CR10 rating of breathing discomfort (0 to 10, higher is worse), assessed before and at the end of the 6-minute walk test.

Week 0 and week 12
Dyspnoea-12 total score
Time Frame: Week 0 and week 12

12 breathlessness descriptors, each scored 0 to 3; total 0 to 36 (higher is worse), with physical (0 to 21) and affective (0 to 15) components.

Week 0 and week 12
Functional class
Time Frame: Week 0 and week 12

NYHA class (I to IV) in heart failure participants, and MRC dyspnoea grade (1 to 5) in all participants. Higher is worse.

Week 0 and week 12
Borg CR10 leg effort
Time Frame: Time Frame: Week 0 and Week 12

Borg CR10 rating of leg effort (0 to 10, higher is worse), assessed before and at the end of the 6-minute walk test.

Time Frame: Week 0 and Week 12

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Qualitative experience, acceptability and context
Time Frame: Within 7 days after the week 12 visit

Semi-structured interviews (30 to 45 minutes) with about 24 to 30 participants on how the fan was used, perceived mechanism, barriers, and effect of heat and humidity. Reflexive thematic analysis.

Within 7 days after the week 12 visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Mohamed Fakhry Ahmed Salem, PHD, Alexandria University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 11, 2026

Primary Completion (Estimated)

February 3, 2027

Study Completion (Estimated)

February 10, 2027

Study Registration Dates

First Submitted

November 2, 2026

First Submitted That Met QC Criteria

November 6, 2026

First Posted (Actual)

November 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FANCP-2026-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.